Theranox

Theranox is a South Korean clinical-stage biotechnology company dedicated to the development of innovative radiosensitizers for the treatment of refractory solid tumors. The company's lead program, TXN-001, is a first-in-class small molecule designed to selectively sensitize hypoxic cancer cells to radiotherapy, addressing a major cause of treatment resistance in aggressive cancers. By enhancing the efficacy of standard radiation therapy, Theranox aims to improve clinical outcomes for patients with glioblastoma, head and neck cancer, and other difficult-to-treat malignancies. The company leverages its expertise in the tumor microenvironment and metabolic pathways to build a pipeline of next-generation oncology therapeutics that synergize with existing standards of care.